PL2124945T3 - Sposób dostarczenia pacjentowi terapii pirfenidonem - Google Patents

Sposób dostarczenia pacjentowi terapii pirfenidonem

Info

Publication number
PL2124945T3
PL2124945T3 PL07865831T PL07865831T PL2124945T3 PL 2124945 T3 PL2124945 T3 PL 2124945T3 PL 07865831 T PL07865831 T PL 07865831T PL 07865831 T PL07865831 T PL 07865831T PL 2124945 T3 PL2124945 T3 PL 2124945T3
Authority
PL
Poland
Prior art keywords
patient
pirfenidone therapy
pirfenidone
discloses
adverse events
Prior art date
Application number
PL07865831T
Other languages
English (en)
Polish (pl)
Inventor
Williamson Ziegler Bradford
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39259551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2124945(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of PL2124945T3 publication Critical patent/PL2124945T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/50—General identification or selection means using icons or symbolic figures, e.g. by a graphical representation symbolising the type of pathology or the organ by an image

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
PL07865831T 2006-12-18 2007-12-18 Sposób dostarczenia pacjentowi terapii pirfenidonem PL2124945T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87059306P 2006-12-18 2006-12-18
PCT/US2007/087988 WO2008077068A1 (en) 2006-12-18 2007-12-18 Method of providing pirfenidone therapy to a patient
EP07865831A EP2124945B1 (en) 2006-12-18 2007-12-18 Method of providing pirfenidone therapy to a patient

Publications (1)

Publication Number Publication Date
PL2124945T3 true PL2124945T3 (pl) 2011-09-30

Family

ID=39259551

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07865831T PL2124945T3 (pl) 2006-12-18 2007-12-18 Sposób dostarczenia pacjentowi terapii pirfenidonem
PL16151564T PL3053580T3 (pl) 2006-12-18 2007-12-18 Sposób dostarczania pacjentowi terapii pirfenidonem

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16151564T PL3053580T3 (pl) 2006-12-18 2007-12-18 Sposób dostarczania pacjentowi terapii pirfenidonem

Country Status (14)

Country Link
US (9) US7767700B2 (enExample)
EP (4) EP3053580B1 (enExample)
JP (1) JP2010513320A (enExample)
AT (1) ATE506060T1 (enExample)
CA (1) CA2667654C (enExample)
CY (1) CY1111699T1 (enExample)
DE (1) DE602007014113D1 (enExample)
DK (1) DK2124945T3 (enExample)
ES (3) ES2581844T3 (enExample)
MX (1) MX2009006526A (enExample)
PL (2) PL2124945T3 (enExample)
PT (1) PT2124945E (enExample)
SI (1) SI2124945T1 (enExample)
WO (1) WO2008077068A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077068A1 (en) 2006-12-18 2008-06-26 Intermune, Inc. Method of providing pirfenidone therapy to a patient
AU2012205256B2 (en) * 2008-11-10 2015-05-28 Intermune, Inc. Pirfenidone Treatment for Patients with Atypical Liver Function
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
HUE058753T2 (hu) 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
HK1220133A1 (zh) 2013-03-15 2017-04-28 Intermune, Inc. 改善微血管完整性的方法
USD731783S1 (en) 2014-04-16 2015-06-16 Abbvie Inc. Template for a prescription medicine container
USD731171S1 (en) 2013-10-07 2015-06-09 Abbvie Inc. Template for a prescription medicine container
USD731782S1 (en) 2013-10-07 2015-06-16 Abbvie Inc. Template for a prescription medicine container
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3432879B1 (en) * 2016-03-22 2021-01-06 Mayo Foundation for Medical Education and Research Using fatty acid synthase inhibitors to treat fibrosis
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2019028062A1 (en) 2017-07-31 2019-02-07 Washington University PIRFENIDONE DERIVATIVES FOR MODULATION OF B-LYMPHOCYTE ACTIVITY AND PROTECTION OF ORGANS
US11052021B2 (en) 2018-03-22 2021-07-06 Abbvie Inc. Medicine container, method of assembling the container, and method of dispensing the medicine from the container
USD930974S1 (en) 2018-03-22 2021-09-21 Abbvie Inc. Child-resistant medication container
USD930973S1 (en) 2018-03-22 2021-09-21 Abbvie Inc. Child-resistant medication container
USD882243S1 (en) 2018-03-26 2020-04-28 Abbvie Inc. Child-resistant medication container assembly
EP3829632A4 (en) * 2018-07-27 2022-05-04 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
GB2589635B (en) * 2019-12-06 2021-12-01 Merxin Ltd Elongate form medicament carrier and medicament dispenser
CN117042738A (zh) * 2021-03-17 2023-11-10 埃科特莱茵药品有限公司 药物剂量系统
WO2023161668A1 (en) 2022-02-28 2023-08-31 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US695044A (en) * 1901-12-28 1902-03-11 Albert E Gibson Non-refillable bottle.
SE9502370D0 (sv) 1995-06-30 1995-06-30 Astra Ab Blister pack, especially for drugs, as well as method and device in manufacturing the same
US6956044B1 (en) * 2000-02-21 2005-10-18 Margolin Solomon B Compositions and methods for treatment of epilepsy
ATE452637T1 (de) * 2001-01-29 2010-01-15 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält
WO2004019863A2 (en) * 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
CA2525647A1 (en) * 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
US20070053877A1 (en) * 2003-08-21 2007-03-08 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
EP2305697A3 (en) * 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20070203202A1 (en) * 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
US20080003635A1 (en) * 2006-06-12 2008-01-03 Intermune, Inc. High Throughput Collagen Synthesis Assay
ATE533486T1 (de) * 2006-06-15 2011-12-15 Shanghai Genomics Inc Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
WO2008077068A1 (en) 2006-12-18 2008-06-26 Intermune, Inc. Method of providing pirfenidone therapy to a patient
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2008144720A2 (en) * 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders

Also Published As

Publication number Publication date
ES2581844T3 (es) 2016-09-07
EP3053580B1 (en) 2021-06-30
ES2395396T3 (es) 2013-02-12
PT2124945E (pt) 2011-07-01
EP2124945B1 (en) 2011-04-20
EP3053580A1 (en) 2016-08-10
US20090197923A1 (en) 2009-08-06
MX2009006526A (es) 2009-06-30
CA2667654A1 (en) 2008-06-26
US20190247380A1 (en) 2019-08-15
US20080194644A1 (en) 2008-08-14
PL3053580T3 (pl) 2021-12-20
US7767700B2 (en) 2010-08-03
US20100324097A1 (en) 2010-12-23
EP2338489A1 (en) 2011-06-29
DE602007014113D1 (de) 2011-06-01
US20180140588A1 (en) 2018-05-24
US8420674B2 (en) 2013-04-16
HK1153647A1 (en) 2012-04-05
EP2471534A1 (en) 2012-07-04
JP2010513320A (ja) 2010-04-30
DK2124945T3 (da) 2011-08-01
US20160324842A1 (en) 2016-11-10
US7696236B2 (en) 2010-04-13
SI2124945T1 (sl) 2011-08-31
ES2882956T3 (es) 2021-12-03
EP2338489B1 (en) 2016-04-27
CA2667654C (en) 2016-12-13
EP2124945A1 (en) 2009-12-02
WO2008077068A1 (en) 2008-06-26
HK1133584A1 (en) 2010-04-01
US20190000821A1 (en) 2019-01-03
US20130220871A1 (en) 2013-08-29
ATE506060T1 (de) 2011-05-15
US20200113884A1 (en) 2020-04-16
CY1111699T1 (el) 2015-10-07

Similar Documents

Publication Publication Date Title
PL2124945T3 (pl) Sposób dostarczenia pacjentowi terapii pirfenidonem
WO2008144241A3 (en) Altering pharmacokinetics of pirfenidone therapy
PH12015500719A1 (en) Gdf-8-inhibitors
HK1198869A1 (en) Combination treatments for hepatitis c
EP2562177A3 (en) Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX346186B (es) Inhibidores de proteina cinasas.
WO2013100567A8 (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
IN2009KN03959A (enExample)
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
DK1965797T3 (da) Nedsættelse af svimmelhed, en bivirkning forbundet med pirfenidonterapi
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
PH12014500381A1 (en) Therapeutic methods
WO2012002773A3 (en) Phenylcarbamate compound and muscle relaxant containing the same
WO2011131370A8 (en) Melt-granulated fingolimod
MX2009006528A (es) Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina.
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
PH12014500684A1 (en) Treatment of rhinitis
WO2009073146A3 (en) Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
WO2011156900A3 (en) Compounds, compositions and methods for treatment of multiple sclerosis
WO2012104838A8 (en) Use of hgh for the treatment of small for gestational age infants under two years of age
WO2012125871A3 (en) Aconitine compounds, compositions, uses, and preparation thereof
WO2009111037A3 (en) Compositions and methods for treating nos-associated diseases